Get more Information

Fill out our inquiry form.

Stem Cell Treatment for SLE

Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which body’s own immune system attacks various body tissues and produces a broad spectrum of signs and symptoms which may involve the skin, heart, lungs, nervous system, kidneys and locomotoive system.

SLE is a progressive disease and patient’s condition tends to get worse in the absence of a proper treatment. Various drugs such as corticosteroids are being used to manage SLE symptoms and to halt the progression of the disease but many of the patients do not respond very well to the drug therapy and those drugs contain serious side effects for long term users.

However, Umbilical Cord derived Mesenchymal Stem Cells (UCMSC) are now available as an effective treatment option for SLE patients. These cells have strong immune mediating properties, can regulate the immune system and suppress the abnormal immune response targeted against the body tissues. Moreover they can promote cell growth and differentiation and stimulate the body’s own stem cells.

Improvements

The combination of the different factors mentioned above can potentially bring improvements in dermatological issues, mobility of the affected joints, pain, cardiac, respiratory and renal functions, cognition and memory, depression and anxiety disorders, disease progression and can lower the frequency of the acute relapses.

*As with any stem cell therapy, improvements may vary from patient to patient and cannot be guaranteed.

Our Treatment Package

Our research based Lupus treatment program the best available worldwide. The combination of Beike stem cell technology with the Functional Medicine Approach of Better Being Hospital allows our patients to give themselves the best chances of improvement. Please review the table below and learn more about the treatments, therapies and services included in our program.

Adult Stem Cell Treatment* 6-8 Injections (16-20 days)
Totaling more than 120 million stem cells

Functional Medicine
&
Rehabilitation**

Correction of Physiological / Blood Imbalances
Nutrition Therapy
Occupational Therapy
Physiotherapy
Hyperbaric Oxygen Therapy
Acupuncture
Aquatherapy

Also Included

Airport pick-up service
Initial examination
24hour medical assistance
English speaking doctors
Top accomodation options to choose from
Patient meals
International staff members assisting every step of the way
*The exact number of stem cell injections will be decided during the acceptance process.
**Depending on each one’s specific condition, not all therapies may be provided.

Treatment Location

Beike Biotechnology is partnered with the Better Being Hospital (BBH) in Bangkok, Thailand. This partnership brings stem cells therapy to another level as BBH is the first accredited center in Asia for functional medicine. Read more about BBH

Injection Methods

The medical team at the center uses intraveinous injections for our patients diagnosed with SLE. More information about this type of injection below:

Intravenous Injection (IV)

The Intravenous (IV) delivery method is a very simple process and should already be familiar to most patients. A tubing line with a catheter tip threaded over a needle is placed into the patient’s vein. Once proper placement is obtained, the needle portion is removed and the flexible plastic catheter is left in place in the vein with the tubing attached. The stem cell solution mixed with the cord blood serum will be administered through the IV (after the evaluation by local medical staff, Dexamethasone may be considered beforehand to avoid any potential allergic reactions). Typically no sedation is required for this procedure. The entire IV injection process takes less than 45 minutes to complete.

Study

SHENZHEN, China, May 13, 2014 – Chinese researchers have recently published new findings in Arthritis Research & Therapy, a top peer-reviewed journal in the field of systemic autoimmune rheumatic diseases, regarding the safety and effectiveness of umbilical cord (UC) derived mesenchymal stem cells (MSCs) in treating 40 patients with severe and refractory Systemic Lupus Erythematosus (SLE). Please click here to read the full study.